Commodore Capital LP Relmada Therapeutics, Inc. Transaction History

Commodore Capital LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$29.55 - $39.15 $4.77 Million - $6.33 Million	-161,565 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$31.52 - $39.28 $535,840 - $667,760	-17,000 Reduced 9.52%	161,565 $5.69 Million
Q4 2020 Feb 16, 2021	BUY	$29.88 - $39.8 $5.34 Million - $7.11 Million	178,565 New	178,565 $5.73 Million

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.3M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Commodore Capital LP, based on Form 13F filings with the SEC.

Stay updated on Commodore Capital LP with notifications on news.